Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5

30Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: High-risk medulloblastoma is defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated with PFS in patients aged 5-19 years with newly diagnosed high-risk medulloblastoma treated according to the phase II trial PNET HR+5. Methods: All children received postoperative induction chemotherapy (etoposide and carboplatin), followed by 2 high-dose thiotepa courses (600 mg/m2) with hematological stem cell support. At the latest 45 days after the last stem cell rescue, patients received risk-Adapted craniospinal radiation therapy. Maintenance treatment with temozolomide was planned to start between 1-3 months after the end of radiotherapy. The primary endpoint was PFS. Outcome and safety analyses were per protocol (all patients who received at least one dose of induction chemotherapy). Results: Fifty-one patients (median age, 8 y; range, 5-19) were enrolled. The median follow-up was 7.1 years (range: 3.4-9.0). The 3 and 5-year PFS with their 95% confidence intervals (95% CI) were 78% (65-88) and 76% (63-86), and the 3 and 5-year OS were 84% (72-92) and 76% (63-86), respectively. Medulloblastoma subtype was a statistically significant prognostic factor (P-value = 0.039) with large-cell/anaplastic being of worse prognosis, as well as a molecular subgroup (P-value = 0.012) with sonic hedgehog (SHH) and group 3 being of worse prognosis than wingless (WNT) and group 4. Therapy was well tolerated. Conclusions: This treatment based on high-dose chemotherapy and conventional radiotherapy resulted in a high survival rate in children with newly diagnosed high-risk medulloblastoma.

References Powered by Scopus

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

11965Citations
N/AReaders
Get full text

The 2007 WHO classification of tumours of the central nervous system

8804Citations
N/AReaders
Get full text

Molecular subgroups of medulloblastoma: The current consensus

1465Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial

21Citations
N/AReaders
Get full text

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

20Citations
N/AReaders
Get full text

High-Dose Chemotherapy in Children with Newly Diagnosed Medulloblastoma

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dufour, C., Foulon, S., Geoffray, A., Masliah-Planchon, J., Figarella-Branger, D., Bernier-Chastagner, V., … Delisle, M. B. (2021). Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. Neuro-Oncology, 23(7), 1163–1172. https://doi.org/10.1093/neuonc/noaa301

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

69%

Researcher 3

23%

Lecturer / Post doc 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

85%

Chemical Engineering 1

5%

Pharmacology, Toxicology and Pharmaceut... 1

5%

Nursing and Health Professions 1

5%

Save time finding and organizing research with Mendeley

Sign up for free